5MWJ

Structure Enabled Discovery of a Stapled Peptide Inhibitor to Target the Oncogenic Transcriptional Repressor TLE1


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.04 Å
  • R-Value Free: 0.219 
  • R-Value Work: 0.188 
  • R-Value Observed: 0.190 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.5 of the entry. See complete history


Literature

Structure-Enabled Discovery of a Stapled Peptide Inhibitor to Target the Oncogenic Transcriptional Repressor TLE1.

McGrath, S.Tortorici, M.Drouin, L.Solanki, S.Vidler, L.Westwood, I.Gimeson, P.Van Montfort, R.Hoelder, S.

(2017) Chemistry 23: 9577-9584

  • DOI: https://doi.org/10.1002/chem.201700747
  • Primary Citation of Related Structures:  
    5MWJ

  • PubMed Abstract: 

    TLE1 is an oncogenic transcriptional co-repressor that exerts its repressive effects through binding of transcription factors. Inhibition of this protein-protein interaction represents a putative cancer target, but no small-molecule inhibitors have been published for this challenging interface. Herein, the structure-enabled design and synthesis of a constrained peptide inhibitor of TLE1 is reported. The design features the introduction of a four-carbon-atom linker into the peptide epitope found in many TLE1 binding partners. A concise synthetic route to a proof-of-concept peptide, cycFWRPW, has been developed. Biophysical testing by isothermal titration calorimetry and thermal shift assays showed that, although the constrained peptide bound potently, it had an approximately five-fold higher K d than that of the unconstrained peptide. The co-crystal structure suggested that the reduced affinity was likely to be due to a small shift of one side chain, relative to the otherwise well-conserved conformation of the acyclic peptide. This work describes a constrained peptide inhibitor that may serve as the basis for improved inhibitors.


  • Organizational Affiliation

    The Institute of Cancer Research, Division of Cancer Therapeutics Unit, Cancer Research UK Cancer Therapeutics Unit, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Transducin-like enhancer protein 1
A, B
337Homo sapiensMutation(s): 0 
Gene Names: TLE1
UniProt & NIH Common Fund Data Resources
Find proteins for Q04724 (Homo sapiens)
Explore Q04724 
Go to UniProtKB:  Q04724
GTEx:  ENSG00000196781 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ04724
Sequence Annotations
Expand
  • Reference Sequence
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.04 Å
  • R-Value Free: 0.219 
  • R-Value Work: 0.188 
  • R-Value Observed: 0.190 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 58.94α = 90
b = 57β = 103.01
c = 104.14γ = 90
Software Package:
Software NamePurpose
BUSTERrefinement
XDSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2017-04-05
    Type: Initial release
  • Version 1.1: 2017-07-26
    Changes: Database references
  • Version 1.2: 2018-10-10
    Changes: Data collection, Source and taxonomy, Structure summary
  • Version 1.3: 2018-10-17
    Changes: Data collection, Source and taxonomy
  • Version 1.4: 2019-10-16
    Changes: Data collection, Structure summary
  • Version 1.5: 2024-01-17
    Changes: Data collection, Database references, Refinement description